ArticleBrazilian journal of microbiology : [publication of the Brazilian Society for Microbiology]2025
Development of RT-LAMP assay for variants of HCV in Pakistan.
Article in Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology], 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis C Virus (HCV) elimination requires improved diagnostic methods, particularly in regions with high screening demands like Pakistan. Rapid and accurate detection is crucial, yet commercially available RT-qPCR assays often have limitations in sensitivity and specificity, reducing their reliability across diverse populations. Additionally, RT-qPCR is time-consuming, costly, and requires skilled personnel. In contrast, Re-verse Transcription-Loop Mediated Isothermal Amplification (RT-LAMP) offers a robust, cost-effective alternative with superior sensitivity and specificity. In the present study, for the first time, we reported a novel RT-LAMP for HCV diagnosis in Pakistan. We designed and optimized an RT-LAMP assay using degenerate primers targeting the 5’ UTR of HCV, incorporating sequences from reference and emerging genotypes, including Pakistani isolates. Key assay parameters, including reaction time, volume, primer concentration, and temperature, were optimized. Triple confirmation of HCV clinical samples using different sets of primers for conventional PCR, commercial lab RT-qPCR and RT-LAMP provided a unique validation approach. It was demonstrated that RT-LAMP detected HCV at a limit of detection of 131 copies, outperforming commercial RT-qPCR by identifying false negatives (71%) and achieving 100% sensitivity and specificity, compared to 82% sensitivity of RT-qPCR. The assay’s processing time was 60 min, supporting large-scale diagnostics. BLAST analysis confirmed specificity, with no significant alignment to related Flaviviridae genomes. RT-LAMP represents a significant advancement in HCV detection, offering high sensitivity, specificity, and ease of use, making it ideal for effective prevention and control strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.